Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer

Yian Wang, Weidong Wen, Jun Yi, Zhongqiu Zhang, Ronald A. Lubet, Ming You

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

In the present study, we examined the effect of bexarotene (Targretin) and budesonide in the chemoprevention of small cell lung carcinoma using a lung-specific knockout model of Rb1 and p53. Upon treatment with bexarotene, tumor incidence, number, and load were significantly reduced (P < 0.05). Budesonide treatment trended to inhibition, but the effect was not statistically significant (P > 0.05). Immunohistochemical staining indicated that bexarotene treatment decreased cell proliferation and increased apoptosis in tumors. The Rb1/ p53 gene-targeted mouse seems to be a valuable model for chemopreventive studies on human small cell lung cancer. Our results indicate that the retinoid X receptor agonist bexarotene may be a potent chemopreventive agent in this cancer type.

Original languageEnglish (US)
Pages (from-to)1059-1064
Number of pages6
JournalCancer Prevention Research
Volume2
Issue number12
DOIs
StatePublished - Dec 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer'. Together they form a unique fingerprint.

Cite this